Sun, Science, and Skin: Dermatology's Biggest Spotlights This June

June is here, and with it comes an issue of Dermatology Times packed with clinically relevant content spanning skin cancer, psoriasis, atopic dermatitis, hidradenitis suppurativa, and more. As the seasons shift and our sun exposure climbs, there is no better moment to revisit Skin Cancer Awareness Month.

MORE FROM JUNE PRINT

As skin cancer takes center stage this month, Todd Schlesinger, MD, FASMS; and Joshua Burshtein, MD, break down what clinicians need to know about immunotherapies for nonmelanoma skin cancer. Complementing that, a data-driven piece from NewBeauty offers a closer look at skin cancer by the numbers, providing the epidemiological context clinicians need to counsel patients and prioritize prevention.

In this month’s cover feature, Burshtein also reports on phase 2 trial data for ruxolitinib cream 1.5% and patients with mild to moderate hidradenitis suppurativa. His review details efficacy outcomes, safety findings, and the potential role of JAK/STAT pathway inhibition in earlier-stage disease management. Readers will also learn how these findings compare with existing topical and systemic treatment options and what they may mean for the future management of HS.

Hossein Akbarialiabad, MD, MSc, HMBA, explores how digital twin technology could reshape dermatology by enabling clinicians to simulate treatment responses using patient-specific biologic, genomic, and environmental data before prescribing therapy. In atopic dermatitis, a deep dive into the oral STAT6 degrader KT-621 highlights its biologics-like efficacy in moderate to severe disease. Emma Guttman-Yassky, MD, PhD, also shares her excitement about the potential for an oral pill with biologic-like results.

Considering practice management, Rivkah Epstein, PA-C, tackles the uncomfortable reality that standard-of-care recommendations are not always realistic for patients. Joseph Gatti, DMSc, MPAS, MBA, PA-C, offers a cautionary tale about online misinformation and contracts, reminding clinicians that when an offer looks too good to be true, the internet may already know why.

As always, Dermatology Times delivers the most up-to-date clinical content, featuring innovative studies, FDA approvals, exclusive interviews, and expert perspectives. Stay informed with the latest data: Subscribe to Dermatology Times’ e-newsletters and follow us on LinkedIn, Instagram, Facebook, X, and YouTube.